MEDBOT-B (02252) announced that according to preliminary internal statistics as of the announcement date, the company's comprehensive order volume for core products including laparoscopic, orthopedic, and vascular intervention systems has cumulatively exceeded 170 units. Among these, the core product Toumai laparoscopic surgical robot has accumulated over 100 commercial orders globally. With nearly 80 Toumai units installed worldwide, the system maintains its leading position among domestic brands, and its commercialization process has entered a stage of comprehensive acceleration.

Based on the company's breakthrough innovative ecosystem that combines robotics and remote technology, Toumai is accelerating to meet multi-level clinical demands in the global market. As of the announcement date, Toumai has cumulatively performed over 15,000 clinical surgeries on humans worldwide.

As the first domestic laparoscopic surgical robot to enter overseas markets, Toumai has achieved over 60 international orders, with installations covering nearly 40 countries and regions across Asia, Europe, Africa, Oceania, and South America. The system has been deployed for large-scale clinical surgeries in mainstream hospital systems across dozens of countries including Italy, Belgium, India, Brazil, Argentina, and the United Arab Emirates.

Recently, the company's commercial deployment in the global high-end medical market achieved another milestone breakthrough. Toumai successfully completed commercial deployment of both single-port and multi-port series at one of the world's top-two medical institutions, successfully implementing a comprehensive intelligent surgical solution.